Progress of guidelines for established and novel agents for myelodysplastic syndromes: reports form the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.02.006
- VernacularTitle:治疗骨髓增生异常综合征的药物介绍:第56届美国血液学会年会报道
- Author:
Xudong TANG
;
Lu ZHANG
;
Feng LIU
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
Drugs;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(2):88-90,100
- CountryChina
- Language:Chinese
-
Abstract:
New progress of guidelines for established and novel agents for myelodysplastic syndromes (MDS) in the 56th American Society of Hematology (ASH) annual meetings was reviewed.MDS was the most commonly diagnosed myeloid malignancy.According to prognostic scoring systems,the MDS patients were divided into lower-risk and higher-risk group.The goal of treatment for lower-risk patients is transfusions minimization and life quality optimization,while the goal of treatment for higher-risk patients is transformation to acute leukemia delay and life prolongation.The lower-risk patients with isolated cytopenia are treated with erythropoiesis-stimulating agents or growth factors.For patients with the del (5q) cytogenetic abnormality or those who were failure in these initial treatment,lenalidomide or experimental agents may be administrated.Lower-risk patients with multiple cytopenia may be treated with immunosuppressive drugs or low-dose hypomethylating agents.For patients with higher-risk disease,hypomethylating agents are the preferred initial treatment approach,with evaluation for hematopoietic cell transplantation at diagnosis.
